Oct 15, 2026 08:31AM
Oct 15, 2026 08:30AM
Oct 15, 2026 08:23AM
Oct 15, 2026 08:22AM
Aug 5, 2026 06:30AM
May 19, 2026 12:07PM
May 11, 2026 08:30AM The Future of Intoxication Detection May Be in Your Voice
May 6, 2026 06:30AM
Mar 25, 2026 07:59AM
Mar 25, 2026 07:59AM
Mar 5, 2026 08:31AM
Mar 5, 2026 08:30AM
Feb 25, 2026 06:30AM
Dec 8, 2025 07:30AM Recursion reports positive trial results for experimental FAP treatment
Dec 8, 2025 07:30AM
Dec 8, 2025 07:30AM
Dec 8, 2025 07:30AM
Nov 18, 2025 08:45AM
Sep 8, 2025 07:01AM
Jul 28, 2025 07:00AM
Jun 4, 2025 02:36PM AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names
May 4, 2025 12:45PM
Apr 29, 2025 08:45AM
Apr 22, 2025 08:34PM
Mar 18, 2025 08:03AM
Mar 18, 2025 08:00AM
Feb 5, 2025 05:27PM
Feb 5, 2025 05:24PM Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Jan 7, 2025 09:15AM
Jan 7, 2025 09:15AM
Jan 7, 2025 09:15AM
Dec 4, 2024 08:45AM
Nov 6, 2024 04:15PM
Oct 2, 2024 02:17PM
Oct 2, 2024 08:02AM Recursion Pharmaceuticals (RXRX) Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphom
Oct 2, 2024 08:00AM
Sep 3, 2024 03:00PM
Sep 3, 2024 02:54PM
Sep 3, 2024 11:50AM
Sep 3, 2024 08:19AM
Sep 3, 2024 08:00AM
Sep 3, 2024 08:00AM Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
Aug 8, 2023 07:58AM
Jun 13, 2023 08:00AM
Sep 13, 2022 07:59AM
Aug 9, 2022 04:15PM
Jul 21, 2022 07:55AM
Jul 21, 2022 07:55AM
Jun 20, 2022 07:55AM Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
May 10, 2022 04:29PM

334,274 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All